SCHEMBL2595570

SCHEMBL2595570

O=C(Nc1cnc(Cl)cn1)Oc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 1/20 0.47
CDK2 P24941 1/20 0.47
CDK5 Q00535 1/20 0.47
ALDH1A1 P00352 5/20 0.46
MAPT P10636 3/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
RAD51 Q06609 1/20 0.45
POLB P06746 1/20 0.45
KCNQ3 O43525 2/20 0.44
KCNQ2 O43526 2/20 0.44
KCNE1 P15382 1/20 0.44
KCNQ1 P51787 1/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27897853 0.85 GAA (0.41) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL29489449 0.83 RAB9A (0.66) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL59952 0.83 RAB9A (0.66) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL305046 0.83 NOTUM (0.52) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL32672056 0.83 NOTUM (0.52) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL31125084 0.82 CHEK1 (0.59) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL2589885 0.82 CHEK1 (0.59) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL1009480 0.82 CCNE1 (0.45) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL1011423 0.81 ALDH1A1 (0.50) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL31028805 0.81 ALDH1A1 (0.50) CCNE1CDK2CDK5ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716287-B2 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED (GB) 2014-05-06 US disclosed
EP-2569290-A2 PHARMACEUTICAL COMPOUNDS Sentinel Oncology Limited (GB) 2013-03-20 EP disclosed
US-20130065900-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2013-03-14 US disclosed
WO-2011141716-A2 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065900-A1 PHARMACEUTICAL COMPOUNDS CSNK1A1, FRK, CSNK1E CCNE1 327/4885CDK2 188/4885CDK5 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.